Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568461 | 1.00 | CCR1 (0.71) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL568695 | 0.93 | CCR1 (0.76) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL12894526 | 0.93 | CCR1 (0.71) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL567500 | 0.93 | CCR1 (0.76) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL567517 | 0.93 | CCR1 (0.70) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL567625 | 0.93 | CCR1 (0.70) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL567101 | 0.92 | CCR1 (0.69) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL568675 | 0.92 | CCR1 (0.69) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL567612 | 0.89 | CCR1 (0.65) | CCR1CYP3A4KCNH2ADRB1 | |
| SCHEMBL568650 | 0.88 | CCR1 (0.65) | CCR1CYP3A4KCNH2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102227425-A | Azaindazole compounds as ccr1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2011-10-26 | — | — | CN | disclosed |
| EP-2346868-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |